TNIP2 (TNFAIP3-interacting protein 2), also known as ABIN2. is a ubiquitin-binding adaptor protein that plays a critical role in regulating NF-κB signaling pathways, inflammation, and apoptosis. It interacts with TNFAIP3 (A20), a key deubiquitinating enzyme, to inhibit NF-κB activation by modulating the ubiquitination status of signaling intermediates like RIPK1 and TRAF6. TNIP2 contains a ubiquitin-binding domain (UBAN) that enables its participation in protein-protein interactions and immune response regulation. Dysregulation of TNIP2 has been implicated in autoimmune diseases, cancers, and inflammatory disorders. For example, reduced TNIP2 expression correlates with increased NF-κB activity in certain cancers, suggesting a tumor-suppressive role.
TNIP2 antibodies are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques such as Western blotting, immunohistochemistry, and co-immunoprecipitation to explore TNIP2's function in cellular models or clinical samples. Commercially available TNIP2 antibodies are typically validated for specificity against human, mouse, or rat isoforms. Research using these antibodies has highlighted TNIP2's involvement in diseases like lupus, psoriasis, and lymphoma, as well as its role in modulating drug resistance in cancer therapy. Reliable TNIP2 antibodies are critical for advancing mechanistic studies and potential therapeutic targeting of TNIP2-associated pathways.